[Liquid perfluorocarbons in vitreo-retinal surgery]. 1998

O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
Service d'Ophtalmologie, Hôpital 20 Août, Casablanca, Maroc.

UI MeSH Term Description Entries
D012163 Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12). Retinal Pigment Epithelial Detachment,Detachment, Retinal,Detachments, Retinal,Retinal Detachments
D005466 Fluorocarbons Liquid perfluorinated carbon compounds which may or may not contain a hetero atom such as nitrogen, oxygen or sulfur, but do not contain another halogen or hydrogen atom. This concept includes fluorocarbon emulsions, and fluorocarbon blood substitutes. Perfluorinated and related polyfluorinated chemicals are referred to as PFAS and are defined as chemicals with at least two adjacent carbon atoms, where one carbon is fully fluorinated and the other is at least partially fluorinated. Fluorocarbon,Fluorocarbon Emulsion,Fluorocarbon Emulsions,Fluorotelomer Phosphate Esters,N-Alkyl Perfluoroalkyl Sulfonamido Carboxylates,PFAS Per- and Polyfluoroalkyl Substances,PFC Perfluorinated Chemicals,PFECAs Perfluoropolyether Carboxylic Acids,Per- and Polyfluoroalkyl Substances,Perfluoroalkane Sulfonamides,Perfluoroalkyl Carboxylates,Perfluoroalkyl Ether Carboxylates,Perfluoroalkyl Polyether Carboxylates,Perfluorocarbon,Perfluorocarbons,Perfluoropolyether Carboxylic Acids,Polyfluorocarbons,Fluorinated Telomer Alcohols,Fluoro-Telomer Alcohols,Polyfluorinated Telomer Alcohols,Telomer Fluorocarbons,Acids, Perfluoropolyether Carboxylic,Alcohols, Fluorinated Telomer,Alcohols, Fluoro-Telomer,Alcohols, Polyfluorinated Telomer,Carboxylates, Perfluoroalkyl,Carboxylates, Perfluoroalkyl Ether,Carboxylates, Perfluoroalkyl Polyether,Carboxylic Acids, Perfluoropolyether,Chemicals, PFC Perfluorinated,Emulsion, Fluorocarbon,Emulsions, Fluorocarbon,Esters, Fluorotelomer Phosphate,Ether Carboxylates, Perfluoroalkyl,Fluoro Telomer Alcohols,Fluorocarbons, Telomer,N Alkyl Perfluoroalkyl Sulfonamido Carboxylates,PFAS Per and Polyfluoroalkyl Substances,Per and Polyfluoroalkyl Substances,Perfluorinated Chemicals, PFC,Phosphate Esters, Fluorotelomer,Polyether Carboxylates, Perfluoroalkyl,Sulfonamides, Perfluoroalkane,Telomer Alcohols, Fluorinated,Telomer Alcohols, Polyfluorinated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014821 Vitrectomy Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma. Vitrectomies
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018630 Vitreoretinopathy, Proliferative Vitreoretinal membrane shrinkage or contraction secondary to the proliferation of primarily retinal pigment epithelial cells and glial cells, particularly fibrous astrocytes, followed by membrane formation. The formation of fibrillar collagen and cellular proliferation appear to be the basis for the contractile properties of the epiretinal and vitreous membranes. Proliferative Vitreoretinopathy,Vitreoretinopathy Neovascular Inflammatory,Inflammatories, Vitreoretinopathy Neovascular,Inflammatory, Vitreoretinopathy Neovascular,Neovascular Inflammatories, Vitreoretinopathy,Neovascular Inflammatory, Vitreoretinopathy,Proliferative Vitreoretinopathies,Vitreoretinopathies, Proliferative,Vitreoretinopathy Neovascular Inflammatories

Related Publications

O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
April 2005, European journal of anaesthesiology,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
January 2022, Seminars in ophthalmology,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
January 1989, Developments in ophthalmology,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
October 2004, European journal of anaesthesiology,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
July 1993, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
October 2004, Nippon Ganka Gakkai zasshi,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
January 1994, International ophthalmology,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
December 1996, Indian journal of ophthalmology,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
April 1993, Ceskoslovenska oftalmologie,
O Benchekroun, and D Lahbil, and R Rachid, and N Laaouissi, and K Zaghloul, and A Amraoui
January 2015, Current pharmaceutical design,
Copied contents to your clipboard!